drugset / Trial / NCT07114016

Efficacy of Topical Glucosamine Versus Corticosteroid in Oral Lichen Planus

NCT07114016

Phase 4 Completed 36 enrolled Future University in Egypt
RandomizedParallel-groupDouble-blindTreatment

Summary

Glucosamine (GlcN) is an N-deacetyl amino sugar derived from the complete hydrolysis of chitosan. It is classified as a nutraceutical and it is used mainly orally for the therapy of osteoarthritis since GlcN has immunoregulatory capacity and anti-inflammatory effects. Given the Oral lichen planus (OLP) T-cell-mediated pathogenesis; this drug seems to be a promising therapeutic option. The investigators compared the clinical efficacy of topical glucosamine to topical corticosteroid in the treatment of symptomatic OLP and investigated the effect of these two treatment modalities on the expression of tumor necrosis factor-alpha (TNF-α) in oral lichen planus lesions

Timeline

Start
2023-05-01
Primary completion
2025-05-15
Completion
2025-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Glucosamine Small molecule 1 % Topical
Comparator Triamcinolone Acetonide Other / unclassified 0.1 %

Indications